ATE232398T1 - Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid - Google Patents

Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid

Info

Publication number
ATE232398T1
ATE232398T1 AT99972932T AT99972932T ATE232398T1 AT E232398 T1 ATE232398 T1 AT E232398T1 AT 99972932 T AT99972932 T AT 99972932T AT 99972932 T AT99972932 T AT 99972932T AT E232398 T1 ATE232398 T1 AT E232398T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
peptide
anticancer agent
composition containing
agent
Prior art date
Application number
AT99972932T
Other languages
English (en)
Inventor
Jamal Temsamani
Michel Kaczorek
De Verdiere Annik Colin
Original Assignee
Synt Em Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt Em Sa filed Critical Synt Em Sa
Application granted granted Critical
Publication of ATE232398T1 publication Critical patent/ATE232398T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99972932T 1998-11-30 1999-11-26 Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid ATE232398T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815073A FR2786398B1 (fr) 1998-11-30 1998-11-30 Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
PCT/FR1999/002939 WO2000032237A1 (fr) 1998-11-30 1999-11-26 Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide

Publications (1)

Publication Number Publication Date
ATE232398T1 true ATE232398T1 (de) 2003-02-15

Family

ID=9533369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972932T ATE232398T1 (de) 1998-11-30 1999-11-26 Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid

Country Status (13)

Country Link
US (1) US7527792B1 (de)
EP (1) EP1135169B1 (de)
JP (1) JP2002538080A (de)
AT (1) ATE232398T1 (de)
AU (1) AU769766B2 (de)
CA (1) CA2352134A1 (de)
DE (1) DE69905392T2 (de)
DK (1) DK1135169T3 (de)
ES (1) ES2192420T3 (de)
FR (1) FR2786398B1 (de)
IL (2) IL143012A0 (de)
PT (1) PT1135169E (de)
WO (1) WO2000032237A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
US7314626B2 (en) 2001-10-16 2008-01-01 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
WO2016077618A1 (en) * 2014-11-12 2016-05-19 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
KR102015524B1 (ko) 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
EP1005357A1 (de) * 1997-04-14 2000-06-07 The Regents Of The University Of California Peptid antiöstrogen-zusammensetzungen und verfahren zur behandlung des brustkrebses
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
FR2830016B1 (fr) 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau

Also Published As

Publication number Publication date
WO2000032237A1 (fr) 2000-06-08
DE69905392T2 (de) 2003-10-09
US7527792B1 (en) 2009-05-05
EP1135169A1 (de) 2001-09-26
IL143012A0 (en) 2002-04-21
EP1135169B1 (de) 2003-02-12
DK1135169T3 (da) 2003-06-10
PT1135169E (pt) 2003-06-30
JP2002538080A (ja) 2002-11-12
DE69905392D1 (de) 2003-03-20
ES2192420T3 (es) 2003-10-01
FR2786398B1 (fr) 2002-12-27
CA2352134A1 (fr) 2000-06-08
AU1391100A (en) 2000-06-19
AU769766B2 (en) 2004-02-05
FR2786398A1 (fr) 2000-06-02
IL143012A (en) 2007-05-15

Similar Documents

Publication Publication Date Title
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
BR9607260A (pt) Utilização de aerogéis em agricultura
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
TR200100824T2 (tr) İleumda safra asidi taşınmasının ve taurokolat alımının inhibitörleri olarak aktifliğe sahip benzotiepinler
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DE69912870D1 (de) Kosmetische oder dermatologische Zusammensetzung, enthaltend zumindest ein natürliches oder rekombinantes Seidenprotein von Arachniden oder ein analoges Protein
PT902789E (pt) Derivados de androsteno
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
DE69905392D1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
UY26431A1 (es) Quimioterapia de combinación
DK0865271T3 (da) Stabiliserede solbeskyttelsespræparater
ZA986720B (en) Photoresponsive sunscreen compositions
FR2687162B1 (fr) Pigments a l'etat de tablettes, leur preparation et leurs utilisations.
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
NZ506005A (en) Recombinant proteins derived from hgf and msp
UA30524A (uk) Мазь для лікування гіперкератозів

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135169

Country of ref document: EP

REN Ceased due to non-payment of the annual fee